Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells

Cancer Letters

Volumn 297, Issue 1, 2010, Pages 31-41

  Arthan, Dumrongkiet ^a   Hong, Seung Keun ^a   Park, Jong In ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Growth inhibition; Leukemia inhibitory factor; Medullary thyroid cancer; Ras Raf; Ret

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; JANUS KINASE; LEUKEMIA INHIBITORY FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN RET; RAF PROTEIN; RAS PROTEIN; STAT3 PROTEIN; CULTURE MEDIUM; LIF PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; RECOMBINANT PROTEIN; RET PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE ACTIVATION; GENETIC VARIABILITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THYROID MEDULLARY CARCINOMA; AUTOCRINE EFFECT; CELL DEATH; CULTURE MEDIUM; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; MEDULLARY CARCINOMA; METABOLISM; MUTATION; PARACRINE SIGNALING; PATHOLOGY; THYROID TUMOR; TIME; TUMOR CELL LINE;

AUTOCRINE COMMUNICATION; CARCINOMA, MEDULLARY; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; JANUS KINASES; LEUKEMIA INHIBITORY FACTOR; MAP KINASE KINASE KINASES; MUTATION; PARACRINE COMMUNICATION; PROTO-ONCOGENE PROTEINS C-RAF; PROTO-ONCOGENE PROTEINS C-RET; RAS PROTEINS; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; THYROID NEOPLASMS; TIME FACTORS; TRANSFECTION;

EID: 77956229707     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.04.021     Document Type: Article

References (51)

1. Kouvaraki M.A., Shapiro S.E., Perrier N.D., Cote G.J., Gagel R.F., Hoff A.O., Sherman S.I., Lee J.E., Evans D.B. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 2005, 15:531-544.
2. Ichihara M., Murakumo Y., Takahashi M. RET and neuroendocrine tumors. Cancer Letters 2004, 204:197-211.
3. Schlumberger M., Carlomagno F., Baudin E., Bidart J.M., Santoro M. New therapeutic approaches to treat medullary thyroid carcinoma. Nature Clinical Practice 2008, 4:22-32.
4. Mooi W.J., Peeper D.S. Oncogene-induced cell senescence - halting on the road to cancer. The New England journal of medicine 2006, 355:1037-1046.
5. Braig M., Schmitt C.A. Oncogene-induced senescence. Putting the brakes on tumor development. Cancer Research 2006, 66:2881-2884.
6. Nakagawa T., Mabry M., De Bustros A., Ihle J.N., Nelkin B.D., Baylin S.B. Introduction of v-Ha-ras oncogene induces differentiation of cultured human medullary thyroid carcinoma cells. Proceedings of the National Academy of Sciences of the United States of America 1987, 84:5923-5927.
7. Wood K.W., Qi H., D'Arcangelo G., Armstrong R.C., Roberts T.M., Halegoua S. The cytoplasmic raf oncogene induces a neuronal phenotype in PC12 cells: a potential role for cellular raf kinases in neuronal growth factor signal transduction. Proceedings of the National Academy of Sciences of the United States of America 1993, 90:5016-5020.
8. Carson E.B., McMahon M., Baylin S.B., Nelkin B.D. Ret gene silencing is associated with Raf-1-induced medullary thyroid carcinoma cell differentiation. Cancer Research 1995, 55:2048-2052.
9. Carson-Walter E.B., Smith D.P., Ponder B.A., Baylin S.B., Nelkin B.D. Post-transcriptional silencing of RET occurs, but is not required, during raf-1 mediated differentiation of medullary thyroid carcinoma cells. Oncogene 1998, 17:367-376.
10. Ravi R.K., Weber E., McMahon M., Williams J.R., Baylin S., Mal A., Harter M.L., Dillehay L.E., Claudio P.P., Giordano A., Nelkin B.D., Mabry M. Activated Raf-1 causes growth arrest in human small cell lung cancer cells. The Journal of Clinical Investigation 1998, 101:153-159.
11. Ravi R.K., Thiagalingam A., Weber E., McMahon M., Nelkin B.D., Mabry M. Raf-1 causes growth suppression and alteration of neuroendocrine markers in DMS53 human small-cell lung cancer cells. American Journal of Respiratory Cell and Molecular Biology 1999, 20:543-549.
12. Fanton C.P., McMahon M., Pieper R.O. Dual growth arrest pathways in astrocytes and astrocytic tumors in response to Raf-1 activation. The Journal of Biological Chemistry 2001, 276:18871-18877.
13. Park J.I., Strock C.J., Ball D.W., Nelkin B.D. The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway. Molecular and Cellular Biology 2003, 23:543-554.
14. Park J.I., Powers J.F., Tischler A.S., Strock C.J., Ball D.W., Nelkin B.D. GDNF-induced leukemia inhibitory factor can mediate differentiation via the MEK/ERK pathway in pheochromocytoma cells derived from nf1-heterozygous knockout mice. Experimental Cell Research 2005, 303:79-88.
15. Vaccaro A., Chen H., Kunnimalaiyaan M. In-vivo activation of Raf-1 inhibits tumor growth and development in a xenograft model of human medullary thyroid cancer. Anti-Cancer Drugs 2006, 17:849-853.
16. Hong S.K., Yoon S., Moelling C., Arthan D., Park J.I. Noncatalytic function of ERK1/2 can promote Raf/MEK/ERK-mediated growth arrest signaling. The Journal of Biological Chemistry 2009, 284:33006-33018.
17. Auernhammer C.J., Melmed S. Leukemia-inhibitory factor-neuroimmune modulator of endocrine function. Endocrine Reviews 2000, 21:313-345.
18. Metcalf D. The unsolved enigmas of leukemia inhibitory factor. Stem cells (Dayton, Ohio) 2003, 21:5-14.
19. Choubey D., Deka R., Ho S.M. Interferon-inducible IFI16 protein in human cancers and autoimmune diseases. Frontiers in Bioscience 2008, 13:598-608.
20. Luan Y., Lengyel P., Liu C.J. P204, a p200 family protein, as a multifunctional regulator of cell proliferation and differentiation. Cytokine & Growth Factor Reviews 2008.
21. Kim E.J., Park J.I., Nelkin B.D. IFI16 is an essential mediator of growth inhibition, but not differentiation, induced by the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells. The Journal of Biological Chemistry 2005, 280:4913-4920.
22. Samuels M.L., Weber M.J., Bishop J.M., McMahon M. Conditional transformation of cells and rapid activation of the mitogen-activated protein kinase cascade by an estradiol-dependent human raf-1 protein kinase. Molecular and Cellular Biology 1993, 13:6241-6252.
23. Kotanides H., Moczygemba M., White M.F., Reich N.C. Characterization of the interleukin-4 nuclear activated factor/STAT and its activation independent of the insulin receptor substrate proteins. The Journal of Biological Chemistry 1995, 270:19481-19486.
24. Park J.I., Strock C.J., Ball D.W., Nelkin B.D. Interleukin-1beta can mediate growth arrest and differentiation via the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells. Cytokine 2005, 29:125-134.
25. He T.C., Zhou S., da Costa L.T., Yu J., Kinzler K.W., Vogelstein B. A simplified system for generating recombinant adenoviruses. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:2509-2514.
26. Klesse L.J., Meyers K.A., Marshall C.J., Parada L.F. Nerve growth factor induces survival and differentiation through two distinct signaling cascades in PC12 cells. Oncogene 1999, 18:2055-2068.
27. Vindelov L.L., Christensen I.J., Nissen N.I. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983, 3:323-327.
28. Sippel R.S., Carpenter J.E., Kunnimalaiyaan M., Chen H. The role of human achaete-scute homolog-1 in medullary thyroid cancer cells. Surgery 2003, 134:866-871.
29. Takahashi M., Buma Y., Taniguchi M. Identification of the ret proto-oncogene products in neuroblastoma and leukemia cells. Oncogene 1991, 6:297-301.
30. Mansour S.J., Matten W.T., Hermann A.S., Candia J.M., Rong S., Fukasawa K., Vande Woude G.F., Ahn N.G. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 1994, 265:966-970.
31. Woods D., Parry D., Cherwinski H., Bosch E., Lees E., McMahon M. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Molecular and Cellular Biology 1997, 17:5598-5611.
32. Zhu J., Woods D., McMahon M., Bishop J.M. Senescence of human fibroblasts induced by oncogenic Raf. Genes & Development 1998, 12:2997-3007.
33. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., Medrano E.E., Linskens M., Rubelj I., Pereira-Smith O., et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:9363-9367.
34. Bromberg J.F., Horvath C.M., Besser D., Lathem W.W., Darnell J.E. Stat3 activation is required for cellular transformation by v-src. Molecular and Cellular Biology 1998, 18:2553-2558.
35. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., Darnell J.E. Stat3 as an oncogene. Cell 1999, 98:295-303.
36. Takahashi C., Contreras B., Iwanaga T., Takegami Y., Bakker A., Bronson R.T., Noda M., Loda M., Hunt J.L., Ewen M.E. Nras loss induces metastatic conversion of Rb1-deficient neuroendocrine thyroid tumor. Nature Genetics 2006, 38:118-123.
37. Hasegawa T., Enomoto A., Kato T., Kawai K., Miyamoto R., Jijiwa M., Ichihara M., Ishida M., Asai N., Murakumo Y., Ohara K., Niwa Y., Goto H., Takahashi M. Roles of induced expression of MAPK phosphatase-2 in tumor development in RET-MEN2A transgenic mice. Oncogene 2008, 27:5684-5695.
38. de Groot J.W., Plaza Menacho I., Schepers H., Drenth-Diephuis L.J., Osinga J., Plukker J.T., Links T.P., Eggen B.J., Hofstra R.M. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations. Surgery 2006, 139:806-814.
39. Gorla L., Mondellini P., Cuccuru G., Micciche F., Cassinelli G., Cremona M., Pierotti M.A., Lanzi C., Bongarzone I. Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements. Molecular Carcinogenesis 2008.
40. Morisi R., Celano M., Tosi E., Schenone S., Navarra M., Ferretti E., Costante G., Durante C., Botta G., D'Agostino M., Brullo C., Filetti S., Botta M., Russo D. Growth inhibition of medullary thyroid carcinoma cells by pyrazolo-pyrimidine derivates. Journal of Endocrinological Investigation 2007, 30:RC31-RC34.
41. Plaza-Menacho I., Mologni L., Sala E., Gambacorti-Passerini C., Magee A.I., Links T.P., Hofstra R.M., Barford D., Isacke C.M. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. The Journal of Biological Chemistry 2007, 282:29230-29240.
42. van Weering D.H., Moen T.C., Braakman I., Baas P.D., Bos J.L. Expression of the receptor tyrosine kinase Ret on the plasma membrane is dependent on calcium. The Journal of Biological Chemistry 1998, 273:12077-12081.
43. Cagnol S., Chambard J.C. ERK and cell death: mechanisms of ERK-induced cell death - apoptosis, Autophagy and senescence. The FEBS Journal 2009, 277:2-21.
44. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nature Reviews 2004, 4:11-22.
45. Farese A.M., Myers L.A., MacVittie T.J. Therapeutic efficacy of recombinant human leukemia inhibitory factor in a primate model of radiation-induced marrow aplasia. Blood 1994, 84:3675-3678.
46. Kurek J.B., Radford A.J., Crump D.E., Bower J.J., Feeney S.J., Austin L., Byrne E. LIF (AM424), a promising growth factor for the treatment of ALS. Journal of the Neurological Sciences 1998, 160(Suppl. 1):S106-113.
47. Davis I.D., Kiers L., MacGregor L., Quinn M., Arezzo J., Green M., Rosenthal M., Chia M., Michael M., Bartley P., Harrison L., Daly M. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clinical Cancer Research 2005, 11:1890-1898.
48. Acosta J.C., O'Loghlen A., Banito A., Guijarro M.V., Augert A., Raguz S., Fumagalli M., Da Costa M., Brown C., Popov N., Takatsu Y., Melamed J., d'Adda di Fagagna F., Bernard D., Hernando E., Gil J. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 2008, 133:1006-1018.
49. Kuilman T., Michaloglou C., Vredeveld L.C., Douma S., van Doorn R., Desmet C.J., Aarden L.A., Mooi W.J., Peeper D.S. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008, 133:1019-1031.
50. Wajapeyee N., Serra R.W., Zhu X., Mahalingam M., Green M.R. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 2008, 132:363-374.
51. Wajapeyee N., Kapoor V., Mahalingam M., Green M.R. Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines. Molecular Cancer Therapeutics 2009, 8:3009-3014.